New pituitary oncogenes

Endocrine-Related Cancer

Volumn 7, Issue 1, 2000, Pages 3-15

  Heaney, A P ^a   Melmed, S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CORTICOTROPIN RELEASING FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOKINE; ESTROGEN; ESTROGEN RECEPTOR; GONADORELIN; GROWTH FACTOR; GROWTH HORMONE RELEASING FACTOR; HORMONE; HYPOTHALAMUS HORMONE; PROTIRELIN; SOMATOSTATIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSCRIPTION FACTOR;

ANGIOGENESIS; CARCINOGENESIS; CELL CLONE; GENE FUNCTION; GENE MUTATION; HORMONAL REGULATION; HUMAN; HYPOPHYSIS TUMOR; MOLECULAR DYNAMICS; NONHUMAN; ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0034068599     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0070003     Document Type: Review

References (101)

1. Adams EF, Winslow CLJ & Mashiter K 1983 Pancreatic growth hormone releasing factor stimulates growth hormone secretion by pituitary cells. Lancet 1 1100-1101.
2. Alexander JM & Klibanski A 1994 Gonadotrophin-releasing hormone receptor mRNA expression by human pituitary tumors in vitro. Journal of Clinical Investigation 93 2332-2339.
3. Alexander JM, Biller BMK, Bikkal H, Zervas NT, Arnold A & Klibanski A 1990 Clinically non-functioning pituitary tumors are monoclonal in origin. Journal of Clinical Investigation 86 336-340.
4. Asa SL, Penz G, Kovacs K & Ezrin C 1982 Prolactin cells in the human pituitary. Archives of Pathology and Laboratory Medicine 106 360-363.
5. Asa SL, Kovacs K, Tindall GT, Barrow DL, Horvath E & Vecsei P 1984 Cushing' s disease associated with an intrasellar gangliocytoma producing corticotrophin-releasing factor. Annals of Internal Medicine 101 789-793.
6. Asa SL, Kovacs K, Stefaneanu L, Horvath E, Billestrup N, Gonzalez-Marcelon C & Vale W 1990 Pituitary mammosomatotroph adenomas develop in old mice transgenic for growth hormone-releasing hormone. Proceedings of the Society for Experimental Biology and Medicine 193 232-235.
7. Asa SL, Kelly MA, Grandy DK & Low MJ 1999 Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor deficient mice. Endocrinology 140 5348-5355.
8. Auemhammer CJ & Melmed S 1999 Interleukin-11 stimulates proopiomelanocortin gene expression and ACTH secretion in corticotroph cells: evidence for a redundant cytokine network in the hypothalamo-pituitary-adrenal axis. Endocrinology 140 1559-1566.
9. Baird A, Mormede P, Ying SP, Wehrenberg WB, Ueno N, Ling N & Guillem R 1985 A nonmitogenic pituitary function of fibroblast growth factor: regulation of thyrotrophin and prolactin secretion. Proceedings of the National Academy of Sciences of the USA 82 5545-5549.
10. Banerjee SK, Sarkar DK, Weston AP, De A & Campbell DR 1997 Overexpression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis. Carcinogenesis 18 1155-1161.
11. Barlier A, Pellegrini-Bouiller F, Gunz G, Zamora AJ, Jaquet P & Enjalbert A 1999 Importance of gsp oncogene on the expression of genes coding for Gs-alpha, Pit-1, G12-alpha, and somatostatin receptor 2 in human adenomas: involvement in octreotide sensitivity. Journal of Clinical Endocrinology and Metabolism 84 2759-2765.
12. Berthrat J, Chanson P & Montmimy M 1995 The cyclic adenosine 3′,5′-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Molecular Endocrinology 9 777-783.
13. Bikfalvi A, Klein S, Pintucci G & Rifkin DB 1997 Biological roles of fibroblast growth factor-2. Endocrine Reviews 18 26-45.
14. Boggild MD, Jenkinson S, Pistorello M, Boscaro M, Scanarini M, McTeman P, Perret CW, Thakker RV & Clayton RN 1994 Molecular genetic studies of sporadic pituitary tumors. Journal of Clinical Endocrinology and Metabolism 78 387-392.
15. Burrow GN, Wotrzman G, Rewcastle NB, Holgate RC & Kovacs K 1981 Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. New England Journal of Medicine 304 156-158.
16. Cai WY, Alexander JM, Hedley-Whyte ET, Scheithauer BW, Jameson JL, Zervas NT & Klibanski A 1994 Ras mutations in human prolactinomas and carcinomas. Journal of Clinical Endocrinology and Metabolism 78 89-93.
17. Chandrasekharappak SC, Guru SC, Manickam P, Olufeni S-E, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL & Marx SJ 1997 Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276 404-406.
18. Costello RT 1936 Subclinical adenoma of the pituitary gland. American Journal of Pathology 12 205-215.
19. Dominguez A, Ramos-Morales F, Romero F, Rios RM, Dreyfuss F, Tortolero M & Pintor-Toro JA 1998 hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Oncogene 17 2187-2193.
20. Dong Q, Brucker-Davis F, Weintraub BD, Smallridge RC, Carr FE, Battey J, Spiegel AM & Shenker A 1996 Screening of candidate oncogenes in human thyrotroph tumors: absence of activating mutations of the Gαq, Gα11, Gαs, or thyrotrophin-releasing hormone receptor genes. Journal of Clinical Endocrinology and Metabolism 81 1134-1140.
21. Farrell WE, Simpson DJ, Bicknell JE, Talbot AS, Bates AS & Clayton RN 1997 Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside the MTS1 and MTS2 genes. Cancer Research 57 2703-2709.
22. Fearon ER & Vogelstein B 1990 A genetic model for colorectal tumorigenesis. Cell 61 759-767.
23. Ferrara N & Davis-Smyth T 1997 The biology of vascular endothelial growth factor. Endocrine Reviews 18 4-25.
24. Folkman J 1992 The role of angiogenesis in tumor growth. Seminars in Cancer Biology 3 65-71.
25. Kip1 mediated two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes and Development 12 2899-2911.
26. Gertz BJ, Contreras LN, McComb DJ, Kovacs K, Tyrell JB & Dallman MF 1987 Chronic administration of corticotrophin-releasing factor increases pituitary corticotroph number. Endocrinology 120 381-388.
27. Godspodarowicz D, Ferrara N, Weigerer L & Neufeld G 1987 Structural characterization and biological functions of fibroblast growth factor. Endocrine Reviews 8 95-114.
28. Greenman Y & Melmed S 1994a Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. Journal of Clinical Endocrinology and Metabolism 78 398-403.
29. Greenman Y & Melmed S 1994b Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSRT5 expression in the mammosomatotroph lineage. Journal of Clinical Endocrinology and Metabolism 79 724-729.
30. Guru SC, Goldsmith PK, Burns AL, Marx SJ, Spiegel AM, Collins FS, & Chandrasekharappak SC 1998 Menin, the product of the MEN1 gene, is a nuclear protein. Proceedings of the National Academy of Sciences of the USA 95 1630-1634.
31. Hashimoto K, Koga M, Motomura T, Kasayama S, Kouharac H, Ohnishi T, Anita N, Hayakawa T, Sato B & Kishimoto T 1995 Identification of alternatively spliced messenger ribonucleic acid encoding truncated growth hormone-releasing hormone. Journal of Clinical Endocrinology and Metabolism 80 2933-2939.
32. 1) and fibroblast growth factor (bFGF) expression in prolactinoma pathogenesis. Nature Medicine 5 1317-1321.
33. Herman V, Fagin J, Gonsky R, Kovacs K & Melmed S 1990 Clonal origins of pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 71 1427-1433.
34. Herman V, Drazin NZ, Gonsky R & Melmed S 1993 Molecular screening of pituitary adenomas for mutations and gene rearrangements. Journal of Clinical Endocrinology and Metabolism 77 50-55.
35. Horvath E, Kovacs K & Scheithauer BW 1999 Pituitary hyperplasia. Pituitary 1 169-180.
36. Jaffrain-Rea ML, Petrangeli E, Ortolani F, Fraioli B, Lise A, Esposito V, Spagnoli LG, Tamburrano G, Frati L & Gulino A 1996 Cellular receptors for sex steroids in human pituitary adenomas. Journal of Endocrinology 15 175-184.
37. Kane LA, Leinung MC, Scheithauer BW, Bergstralh EJ, Laws ER Jr, Groover RV, Kovacs K, Horvath E & Zimmerman D 1994 Pituitary adenomas in childhood and adolescence. Journal of Clinical Endocrinology and Metabolism 79 1135-1140.
38. Karga HJ, Alexander JM, Hedley-Whyte ET, Klibansky A & Jamesom LJ 1992 ras mutations in human pituitary tumors. Journal of Clinical Endocrinology and Metabolism 74 914-919.
39. Kontogeorgos G, Kovacs K, Horvath E & Scheithauer BW 1991 Multiple adenomas of the human pituitary. A retrospective study with clinical implications. Journal of Neurosurgery 74 243-247.
40. Kovacs K & Horvath E 1986 Tumors of the pituitary gland. In Atlas of Tumor Pathology, Second Series, Fasicle 21, p 571. Eds WH Hartmann & LH Sobin. Washington, DC: Armed Forces Institute of Pathology.
41. Kovacs K, Ryan N, Horvath E, Ezrin G & Penz G 1978 Prolactin cell adenomas of the human pituitary. Morphological features of prolactin cells in the nontumorous portions of the anterior lobe. Hormone and Metabolic Research 10 409-412.
42. Kovacs K, Stefaneanu L, Ezzat S & Smyth HS 1994 Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study. Archives of Pathology and Laboratory Medicine 118 562-565.
43. Lamonerie T, Tremblay JJ, Lanctot C, Therrien M, Gauthier Y & Drouin J 1996 Ptx1, a bicoid-related homeo box transcription factor involved in transcription of the proopio-melanocortin gene. Genes and Development 10 1284-1295.
44. Larson GH, Koos RD, Sortino MA & Wise PM 1990 Acute effects of basic fibroblast growth factor on secretion of prolactin as assessed by the reverse hemolytic plaque assay. Endocrinology 126 927-932.
45. Larsson C, Skogseid B, Oberg K, Nakamura Y & Nordenskjold M 1988 Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 322 85-87.
46. Le Dafniet M, Blumberg-Tick J, Gozlan H, Barret A, Joubert Bression D & Peillon F 1989 Altered balance between thyrotrophin-releasing hormone and dopamine in prolactinomas and other pituitary tumors compared to normal pituitaries. Journal of Clinical Endocrinology and Metabolism 69 267-271.
47. Le Dafniet M, Lefebvre P, Barret A, Mechain C, Feinstein MC, Brandi Am & Peillon F 1990 Normal and adenomatous human pituitaries secrete thyrotrophin-releasing hormone in vitro: modulation by dopamine, haloperidol, and somatostatin. Journal of Clinical Endocrinology and Metabolism 71 480-486.
48. Levy L, Bourdais J, Mouhieddine OE, Berlot C, Villares S, Cohen P, Peillon F & Joubert D 1993 Presence and characterization of the somatostatin precursor in normal pituitaries and in growth-hormone secreting adenomas. Journal of Clinical Endocrinology and Metabolism 76 85-90.
49. Lidhar K, Korbonits M, Jordan S, Khalimova Z, Kaltsas G, Lu X, Clayton RN, Jenkins PJ, Monson JP, Besser GM, Lowe DG & Grossman AB 1999 Low expression of the cell cycle inhibitor p27KIP1 in normal corticotroph cells, corticotroph tumors and malignant pituitary tumors. Journal of Clinical Endocrinology and Metabolism 84 3833-3830.
50. McAndrew J, Paterson AJ, Asa SL, McCarthy KJ & Kudlow JE 1995 Targeting of transforming growth factor-α expression to pituitary lactotrophs in transgenic mice results in lactotroph proliferation and adenomas. Endocrinology 136 4479-4488.
51. McNichol AM, Kubba MAG & McTeague E 1988 The mitogenic effects of corticotrophin-releasing factor on the anterior pituitary gland of the rat. Journal of Endocrinology 118 237-241.
52. Melmed S 1998 Pituitary function and neoplasia. In Principles of Molecular Medicine Textbook, pp 443-449. Ed. L Jameson. Totowa, NJ: Humana Press.
53. Melmed S 1999 Pathogenesis of pituitary tumors. Endocrine and Metabolic Clinics of North America 28 1-12.
54. Molitch ME & Russell EJ 1990 The pituitary 'incidentaloma'. Annals of Internal Medicine 112 925-931.
55. Mukai K, Steljeskog EL & Dehner LP 1986 Pituitary adenomas in patients under 20 years old. A clinicopathological study of 12 cases. Journal of Neurooncology 4 79-89.
56. Nakamura S, Ohtsura A, Takamura N, Kitange G, Tokunaga Y, Yasunaga A, Shibata S & Yamashita S 1999 Prop-1 gene expression in human pituitary tumors. Journal of Clinical Endocrinology and Metabolism 84 2581-2584.
57. Nakao H, Koga M, Arao N, Kakao M, Sato B, Kishimono S, Saitoh Y, Arita N & Mori S 1989 Enzyme immunoassay for estrogen receptor in human pituitary adenomas. Acta Endocrinologica 120 233-238.
58. Nicolis G, Shimshi M, Allen C, Halmi NS & Kourides IA 1988 Gonadotrophin-producing pituitary adenoma in a man with long-standing primary hypothyroidism. Journal of Clinical Endocrinology and Metabolism 66 237-241.
59. Nishikawa R, Cheng SY, Nagashima R, Huang HJ, Cavenee WK & Matsutani M 1998 Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathologica 96 453-462.
60. Okuda K, Yoshikawa M, Ushiroyama T, Sugimoto O, Maeda T & Mori H 1989 Two patients with hypergonadotrophic ovarian failure due to pituitary hyperplasia. Obstetrics and Gynecology 74 498-501.
61. Pagotto JU, Paez MP, Arzt E, Stalla GK & Renner U 1999 Pituitary adenylate cyclase-activating polypeptide, interleukin-6 and glucocorticoids regulate the release of vascular endothelial growth factor in pituitary folliculostellate cells. Journal of Endocrinology 160 483-490.
62. Pei L & Melmed S 1997 Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Molecular Endocrinology 11 433-441.
63. Pei L, Melmed S, Scheithauer B, Kovacs K & Prager D 1994 H-ras mutations in human pituitary carcinoma metastasis. Journal of Clinical Endocrinology and Metabolism 78 842-846.
64. Pei L, Melmed S, Scheithauer BW, Kovacs K, Benedict WF & Prager D 1995 Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Research 55 1613-1616.
65. Prezant TP, Levine J & Melmed S 1998 Molecular characterization of the Menl tumor suppressor gene in sporadic pituitary tumors. Journal of Clinical Endocrinology and Metabolism 83 1388-1391.
66. Prezant TP, Kadioglu P & Melmed S 1999 An intronless homolog of human proto-oncogene hPTTG is expressed in pituitary tumors: evidence for hPTTG family. Journal of Clinical Endocrinology and Metabolism 84 1149-1152.
67. Qian X, Jin L, Kulig E & Lloyd RV 1998 DNA methylation regulates p27kip1 expression in rodent pituitary cell lines. American Journal of Pathology 153 1475-1482.
68. Renner U, Gloddek J, Pereda MP, Arzt E & Stalla GK 1998 Regulation and role of intrapituitary IL-6 production by folliculostellate cells. Domestic Animal Endocrinology 15 353-362.
69. Riedl S & Frisch H 1997 Pituitary hyperplasia in a girl with gonadal dysgenesis and primary hypothyroidism. Hormonal Research 47 126-130.
70. Sakamoto H, Mori M, Taira M, Yoshida T, Matsukawa S, Shimiz K, Sekiguchi M, Terada M & Sugimura T 1986 Transforming gene from human stomach cancers and non-cancerous portion of stomach mucosa. Proceedings of the National Academy of Sciences of the USA 83 3997-4001.
71. Sano T, Asa SL & Kovacs K 1988 Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations. Endocrine Reviews 9 357-373.
72. Sarlis NJ, Brucker-Davis F, Doppman H & Skarulis MC 1997 MRI-demonstrable regression of a pituitary mass after a week of acute thyroid hormone therapy. Journal of Clinical Endocrinology and Metabolism 82 808-811.
73. Schlechter J & Weiner R 1991 Changes in basic fibroblast growth factor coincident with estradiol-induced hyperplasia of the anterior pituitary of Fischer 344 and Sprague-Dawley rats. Endocrinology 129 2400-2488.
74. Schechter J, Goldsmith P, Wislon C & Weiner R 1988 Morphological evidence for the presence of arteries in human prolactinomas. Journal of Clinical Endocrinology and Metabolism 67 713-719.
75. Scheithauer BW, Kovacs K & Randall RV 1983 The pituitary gland in untreated Addison's disease. A histologic and immunocytologic study of 18 adenohypophyses. Archives of Pathology and Laboratory Medicine 107 484-487.
76. Scheithauer BW, Kovacs K, Randall RV & Ryan N 1985 Pituitary gland in hypothyroidism: histologic and immunocytologic study. Archives of Pathology and Laboratory Medicine 109 499-504.
77. Serrano M, Lee HW, Chin C, Cordon-Cardos C, Beach D & DePinho RA 1996 Role of the INK4a locus in tumor suppression and cell mortality. Cell 85 27-37.
78. Sherr CJ & Roberts JM 1995 Inhibitors of mammalian G1 cyclin-dependent kinases. Genes and Development 91149-1163.
79. Shimon I, Huttner A, Said J, Spirina OM & Melmed S 1996 Heparin-binding secretory transforming gene (hst) facilitates rat lactotrope cell tumorigenesis and induces prolactin gene transcription. Journal of Clinical Investigation 97 187-195.
80. Shimon I, Hinton DR, Weiss MH & Melmed S 1998 Prolactinomas express human heparin-binding secretory transforming gene product: marker of tumor invasiveness. Clinical Endocrinology 48 23-29.
81. Simpson DJ, Magnay J, Bicknell JE, Barkan AL, McNicol AM, Clayton RN & Farrell WE 1999 Chromosome 13q deletion mapping in pituitary tumors: infrequent loss of the retinoblastoma susceptibility gene (RB1) locus despite loss of RB1 protein product in somatotrophinomas. Cancer Research 59 1562-1566.
82. Snyder PJ 1985 Gonadotroph cell adenomas of the pituitary. Endocrine Reviews 6 552-563.
83. Sornson MW, Wu W, Dasen JS, Flynn SE, Norman DJ, O'Connell SM, Gukovsky I, Carriere C, Ryan AK, Miller AP, Zuo L, Glieberman AS, Anderson B, Beamer WG & Rosenfeld MG 1996 Pituitary lineage determination by the prophet of Pit-1 homeodomain factor defective in Ames dwarfism. Nature 384 327-333.
84. Spada A, Elahi FR, Arosio M, Sartorio A, Guglielmo L, Vallar L & Faglia G 1987 Lack of desensitization of adenomatous somatotrophs to growth hormone releasing-hormone in acromegaly. Journal of Clinical Endocrinology and Metabolism 64 585-591.
85. Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar L, Basetti M & Faglia G 1990 Clinical, biochemical and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenyl cyclase. Journal of Clinical Endocrinology and Metabolism 71 1421-1426.
86. Stefeananu L, Kovacs K, Horvath E, Lloyd RV, Buchfelder M, Fahlbusch R & Smyth H 1994 In situ hybridisation study of estrogen receptor messenger ribonucleic acid in human adenohypophyseal cells and pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 78 83-88.
87. Struthers RS, Vale WW, Arias C, Sawchenko PE & Montminy MR 1991 Somatroph hyperplasia and dwarfism in transgenic mice expressing a non-phosphorylatable CREB mutant. Nature 350 622-624.
88. Suda T, Tozawa F, Dobasi I, Horiba N, Ohmori N, Yamakado M, Yamada M & Demura H 1993 Corticotrophin-releasing hormone, proopiomelanincortin, and glucocorticoid receptor gene expression in adrenocorticotrophin-producing tumors in vitro. Journal of Clinical Investigation 92 2790-2795.
89. Sulliman ME, Royds JA, Baxter L, Timperley WR, Cullen DR & Jones TH 1999 IL-8 mRNA expression by in situ hybridisation in human pituitary adenomas. European Journal of Endocrinology 140 155-158.
90. Tanaka C, Kimura T, Yang P, Moritani M, Yamaoka T, Yamada S, Sano T, Yoshimoto K & Itakura M 1998 Analysis of loss of heterozygosity on chromosome 11 and infrequent inactivation of MEN1 gene in sporadic pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 83 2631-2634.
91. Terada T, Kovacs K, Stefaneanu L & Horvath E 1995 Incidence, pathology and recurrence of pituitary adenomas: study of 647 unselected surgical cases. Endocrine Pathology 6 301-310.
92. Wang Z & Melmed S 2000 characterisation of the murine pituitary tumor transforming gene (PTTG) and its promoter. Endrocrinology 141 763-771.
93. Weinberg RA 1995 The retinoblastoma protein and cell cycle control. Cell 81 323-330.
94. Weiner R, Elias KA & Monet F 1985 The role of vascular changes in the etiology of prolactin secreting anterior pituitary tumors. In Prolactin. Basic and Clinical Correlates, pp 641-653. Eds RM MacLeod, MO Thorner & U Scapagnini. Padova: Livinia Press.
95. Woloschak M, Yu A, Xiao J & Post KD 1992 Abundance and state of phosphorylation of the retinoblastoma gene product in human pituitary tumors. International Journal of Cancer 67 16-19.
96. Wu W, Cogan JD, Pfaffle RW, Dasen JS, Frisch H, O'Connell SM, Flynn SE, Brown MR, Mullis PE, Parks JS, Phillips JAI & Rosenfeld MG 1998 Mutations in PROP1 cause familial combined pituitary hormone deficiency. Nature Genetics 18 147-149.
97. Yoshimoto K, Iwahana H, Fukada A, Sano T & Itakura M 1993 Rare mutations of the Gs alpha subunit gene in human endocrine tumors: mutation detection by polymerase chain reaction-primer-introduced restriction analysis. Cancer 72 1386-1393.
98. Zhang X, Horwitz GA, Prezant TP, Bronstein M, Valentini A & Melmed S 1999a Structure, expression and function of human pituitary transforming gene (PTTG). Molecular Endocrinology 13 156-166.
99. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Bronstein M & Melmed S 1999b Pituitary tumor transforming gene expression in human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 84 761-767.
100. Zimmering MB, Katsumato N, Sato Y, Brandi ML, Aurbach GD & Marx SJ 1993 Increased basic fibroblast growth factor in plasma from multiple endocrine neoplasia type-1: relation to pituitary tumor. Journal of Clinical Endocrinology and Metabolism 76 1182-1187.
101. Zou H, McGarry TJ, Bernai T & Kirschner MW 1999 Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285 418-122.